Sponsor or institution

Clinical trials and research at Nanjing Leads Biolabs Co.,Ltd

• 12Clinical trials
• 1Country

Newest trials

All recruiting trials (12)

• LBL-024 combo therapy for metastatic colorectal cancer in adults

  This trial tests whether adding LBL-024 to a combo of standard cancer drugs can help adults with metastatic colorectal cancer.

  Recruiting Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Guangzhou, Guangdong and 9 other locations · NCT07791758

• LBL-024 combined with chemotherapy and immunotherapy for advanced gastric or gastroesophageal junction adenocarcinoma

  This study will test whether adding LBL-024 to capecitabine, oxaliplatin, and tislelizumab helps adults with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

  Recruiting Phase 2 Nanjing Leads Biolabs Co.,Ltd · Beijing, Beijing Municipality and 6 other locations · NCT07390383

• LBL-024 combination treatment for advanced esophageal squamous cell carcinoma (Phase II, Substudy 03)

  This trial tries LBL-024 combined with chemotherapy and immunotherapy in adults with advanced esophageal squamous cell carcinoma to see if it better controls tumors or prolongs benefit.

  Recruiting at 6 sites Phase 2 Nanjing Leads Biolabs Co.,Ltd · Beijing, Beijing Municipality and 6 other locations · NCT07331155

• Testing a single subcutaneous injection of LBL-047 in healthy adults and people with systemic lupus erythematosus

  This will test whether a single under-the-skin injection of LBL-047 is safe and shows early benefit for healthy adults and adults with mild to moderate systemic lupus erythematosus.

  Recruiting at 11 sites Phase 1 Nanjing Leads Biolabs Co.,Ltd · Bengbu, Anhui and 11 other locations · NCT07323173

• LBL-024 alone or with chemotherapy for recurrent or metastatic triple-negative breast cancer

  This trial tests whether LBL-024 by itself or together with albumin-bound paclitaxel can shrink tumors or slow disease in people with recurrent or metastatic triple-negative breast cancer.

  Recruiting at 7 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Guangzhou, Guangdong and 6 other locations · NCT07281976

• LBL-024 combined treatment for advanced biliary tract cancer and hepatocellular carcinoma.

  This study tests whether LBL-024 given with chemotherapy and bevacizumab helps adults with advanced biliary tract cancer or hepatocellular carcinoma.

  Recruiting at 8 sites Phase 2 Nanjing Leads Biolabs Co.,Ltd · Hefei, Anhui and 15 other locations · NCT07111546

• LBL-024 alone or combined with LBL-007 or toripalimab for advanced melanoma

  This research will test whether LBL-024, given alone or with LBL-007 or with the PD-1 drug toripalimab, helps people with advanced melanoma.

  Recruiting at 10 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Beijing, Beijing Municipality and 15 other locations · NCT07099430

• LBL-024 combined with paclitaxel for platinum-resistant ovarian cancer

  This trial tests whether adding the new drug LBL-024 to paclitaxel helps people with platinum-resistant ovarian cancer and is safe.

  Recruiting at 8 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Beijing, Beijing Municipality and 12 other locations · NCT07042802

• LBL-024 combination therapy for advanced non-small cell lung cancer (NSCLC)

  This study tests whether adding LBL-024 to chemotherapy or other cancer drugs helps people with advanced NSCLC respond better or live longer.

  Recruiting at 24 sites Phase 2 Nanjing Leads Biolabs Co.,Ltd · Hefei, Anhui and 23 other locations · NCT06783647

• Combining LBL-024 with Etoposide and Platinum for Advanced Neuroendocrine Carcinoma

  This study is testing if a new drug called LBL-024, when combined with standard chemotherapy, can help people with advanced neuroendocrine carcinoma who haven't had treatment before.

  Recruiting at 25 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Hefei, Anhui and 24 other locations · NCT06157827

• Testing LBL-034 for patients with relapsed refractory multiple myeloma

  This study is testing a new treatment called LBL-034 to see if it can help people with relapsed or refractory multiple myeloma feel better.

  Recruiting at 21 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Wuhu, Anhui and 20 other locations · NCT06049290

• Testing LBL-024 in patients with advanced malignant tumors

  This study is testing a new drug called LBL-024 to see if it can help people with advanced cancer that hasn't responded to other treatments.

  Recruiting at 49 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Hefei, Anhui and 48 other locations · NCT05170958

Quick answers

How many clinical trials run by Nanjing Leads Biolabs Co.,Ltd are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 7, Phase 2: 4, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →